Literature DB >> 21358202

A method to estimate total entry to hard drug use: the case of intravenous drug use in Norway.

Ellen J Amundsen1, Anne Line Bretteville-Jensen, Ludwig Kraus.   

Abstract

BACKGROUND/AIMS: Epidemiological measures such as the prevalence and incidence of hard drug use are important tools for evaluating drug situations and drug policies. Models for drug use trajectories illustrate how temporary and lasting cessation of and relapse into hard drug use are other important elements in the overall picture of change in hard drug use over time. Estimating the total entry to hard drug use broadens the knowledge of the change in such use.
METHODS: The entry rate for hard drug use is defined as the sum of incident cases and relapses and estimated based on successive prevalence estimates and cessation rates.
RESULTS: The entry rate, as applied to the Norwegian case of intravenous drug use, increased from the mid-1980s to a peak in 2000, decreased up to 2003 and stabilized thereafter. The peak in Oslo appeared earlier (1998). The estimated level of the entry rate is sensitive to the rate of cessation.
CONCLUSION: We conclude that it is possible to expand the description of hard drug use epidemics beyond estimates of prevalence and incidence. The entry rate supplies a useful tool for our understanding of drug situations and decision making regarding drug policies.
Copyright © 2011 S. Karger AG, Basel.

Mesh:

Year:  2011        PMID: 21358202     DOI: 10.1159/000324341

Source DB:  PubMed          Journal:  Eur Addict Res        ISSN: 1022-6877            Impact factor:   3.015


  2 in total

1.  A multi-state model to estimate incidence of heroin use.

Authors:  Albert Sánchez-Niubò; Odd O Aalen; Antònia Domingo-Salvany; Ellen J Amundsen; Josep Fortiana; Kjetil Røysland
Journal:  BMC Med Res Methodol       Date:  2013-01-14       Impact factor: 4.615

2.  On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017.

Authors:  Christer Frode Aas; Jørn Henrik Vold; Svetlana Skurtveit; Ingvild Odsbu; Fatemeh Chalabianloo; Jan Magnus Økland; Rafael Alexander Modahl Leiva; Peter Vickerman; Kjell Arne Johansson; Lars T Fadnes
Journal:  BMJ Open       Date:  2020-08-26       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.